AstraZeneca working to eliminate risk of blood clots from vaccine


AstraZeneca working to eliminate risk of blood clots from vaccine

AstraZeneca and Johnson & Johnson are investigating how to tweak their vaccine to preclude the risk of blood clots.

The companies are understood to be conducting laboratory work to understand the molecular mechanism that may cause the complication, with a view to potentially producing a modified version.

It comes after data showed a probable causal link between the jabs and an extremely small chance of fatal blood clots.

The risk has prompted watchdogs to restrict the AstraZeneca jab to those aged 40 and older.

The risks of clotting combined with low blood platelets—a rare condition termed vaccine-induced immune thrombotic thrombocytopenia, or VITT—following the AstraZeneca shot are roughly 1 to 2 per 100,000 vaccinations, according to U.K. and European tallies of cases.

Meanwhile U.S. government data show a lower rate of around 0.3 instances of the clotting condition per 100,000 doses for the J&J vaccine. 

Read Original – Click Here


Tags:
0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

©2021 U-K-News.Com - News Network

Log in with your credentials

or    

Forgot your details?

Create Account